| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| SOXC Transcription Factors | 4 | 2014 | 58 | 1.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2014 | 2850 | 0.610 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 2 | 2007 | 72 | 0.510 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2014 | 31 | 0.490 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2007 | 254 | 0.470 |
Why?
|
| Wnt Signaling Pathway | 2 | 2014 | 446 | 0.440 |
Why?
|
| Homeodomain Proteins | 2 | 2019 | 1149 | 0.440 |
Why?
|
| B-Lymphocytes | 3 | 2014 | 1353 | 0.430 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2014 | 1127 | 0.400 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 696 | 0.380 |
Why?
|
| Biopsy, Fine-Needle | 6 | 2020 | 699 | 0.360 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2020 | 570 | 0.330 |
Why?
|
| Immunophenotyping | 4 | 2014 | 1701 | 0.290 |
Why?
|
| Immunohistochemistry | 11 | 2020 | 7704 | 0.290 |
Why?
|
| Dendritic Cells, Follicular | 2 | 2005 | 39 | 0.290 |
Why?
|
| Receptors, Cytokine | 1 | 2008 | 184 | 0.290 |
Why?
|
| Chromosome Inversion | 2 | 2007 | 183 | 0.280 |
Why?
|
| Leukemia, Hairy Cell | 2 | 2004 | 121 | 0.280 |
Why?
|
| Myelolipoma | 1 | 2006 | 12 | 0.270 |
Why?
|
| Lumbosacral Region | 1 | 2006 | 52 | 0.270 |
Why?
|
| Hyaluronan Receptors | 2 | 2005 | 255 | 0.260 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 4911 | 0.250 |
Why?
|
| Paraproteinemias | 1 | 2004 | 61 | 0.230 |
Why?
|
| Flow Cytometry | 4 | 2014 | 3074 | 0.230 |
Why?
|
| Cell Differentiation | 2 | 2014 | 4168 | 0.230 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 2520 | 0.220 |
Why?
|
| Cadherins | 2 | 2005 | 675 | 0.220 |
Why?
|
| Castleman Disease | 1 | 2003 | 72 | 0.220 |
Why?
|
| Apoptosis | 9 | 2013 | 7759 | 0.210 |
Why?
|
| Muscle, Smooth | 1 | 2003 | 244 | 0.200 |
Why?
|
| Organ Transplantation | 1 | 2004 | 200 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 3238 | 0.190 |
Why?
|
| Cell Division | 2 | 2003 | 2556 | 0.190 |
Why?
|
| Lymphoma, Follicular | 2 | 2003 | 604 | 0.180 |
Why?
|
| Synaptophysin | 1 | 2020 | 79 | 0.180 |
Why?
|
| Biomarkers, Tumor | 9 | 2020 | 10627 | 0.180 |
Why?
|
| Carcinoid Tumor | 1 | 2002 | 283 | 0.180 |
Why?
|
| Chromogranin A | 1 | 2020 | 65 | 0.180 |
Why?
|
| Breast Neoplasms, Male | 1 | 2002 | 233 | 0.180 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 5242 | 0.180 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2018 | 511 | 0.170 |
Why?
|
| Immunoglobulins | 1 | 2020 | 268 | 0.170 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 709 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 2 | 2005 | 1577 | 0.170 |
Why?
|
| Immunoenzyme Techniques | 5 | 2014 | 1183 | 0.170 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2019 | 23 | 0.170 |
Why?
|
| Genes, BRCA1 | 1 | 2002 | 395 | 0.170 |
Why?
|
| Gene Rearrangement | 2 | 2013 | 797 | 0.160 |
Why?
|
| Indoles | 2 | 2015 | 1021 | 0.160 |
Why?
|
| Cytokines | 1 | 2008 | 2871 | 0.160 |
Why?
|
| Testis | 1 | 2003 | 739 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2020 | 1699 | 0.160 |
Why?
|
| BRCA1 Protein | 1 | 2002 | 518 | 0.160 |
Why?
|
| Multiple Myeloma | 2 | 2014 | 2237 | 0.160 |
Why?
|
| Mutation Rate | 1 | 2019 | 230 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 418 | 0.140 |
Why?
|
| Sarcoma | 3 | 2005 | 1830 | 0.140 |
Why?
|
| Transcription Factors | 4 | 2019 | 5362 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2003 | 909 | 0.140 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 2 | 2013 | 47 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2018 | 1228 | 0.130 |
Why?
|
| Middle Aged | 20 | 2020 | 89535 | 0.130 |
Why?
|
| Cell Line, Tumor | 7 | 2019 | 14855 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 2425 | 0.130 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2020 | 412 | 0.130 |
Why?
|
| Humans | 39 | 2020 | 270842 | 0.130 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2013 | 173 | 0.130 |
Why?
|
| Cell Cycle | 2 | 2013 | 2117 | 0.130 |
Why?
|
| Arylsulfotransferase | 1 | 2015 | 19 | 0.130 |
Why?
|
| Janus Kinase 2 | 2 | 2010 | 738 | 0.120 |
Why?
|
| ErbB Receptors | 1 | 2003 | 2329 | 0.120 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2013 | 5 | 0.120 |
Why?
|
| Male | 19 | 2020 | 127630 | 0.120 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 620 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 649 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 2589 | 0.110 |
Why?
|
| Aged | 16 | 2020 | 72902 | 0.110 |
Why?
|
| Mice | 9 | 2014 | 35331 | 0.110 |
Why?
|
| Lymphoma, B-Cell | 2 | 2014 | 924 | 0.110 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2013 | 34 | 0.110 |
Why?
|
| Prodrugs | 1 | 2014 | 220 | 0.110 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 2012 | 11 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2012 | 9067 | 0.100 |
Why?
|
| Bone Marrow | 2 | 2013 | 2381 | 0.100 |
Why?
|
| Female | 22 | 2020 | 147292 | 0.100 |
Why?
|
| Carcinoma | 3 | 2005 | 2601 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2013 | 276 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2014 | 450 | 0.100 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 151 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2020 | 7068 | 0.100 |
Why?
|
| Adult | 14 | 2020 | 80709 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1083 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 589 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2012 | 221 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 1057 | 0.090 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 260 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 2397 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2013 | 12151 | 0.090 |
Why?
|
| Lymph Nodes | 3 | 2014 | 3033 | 0.090 |
Why?
|
| Prognosis | 7 | 2020 | 22249 | 0.090 |
Why?
|
| SEER Program | 1 | 2014 | 1019 | 0.090 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2003 | 3065 | 0.090 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 30813 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 1411 | 0.090 |
Why?
|
| Animals | 9 | 2014 | 61014 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2341 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 309 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2009 | 56 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2013 | 1288 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 5239 | 0.080 |
Why?
|
| beta Catenin | 1 | 2013 | 697 | 0.080 |
Why?
|
| Protein Phosphatase 2 | 1 | 2009 | 88 | 0.080 |
Why?
|
| Disease Progression | 2 | 2014 | 6891 | 0.080 |
Why?
|
| Mice, SCID | 1 | 2013 | 1864 | 0.080 |
Why?
|
| Immunoglobulin M | 2 | 2013 | 355 | 0.080 |
Why?
|
| Chemokine CCL11 | 1 | 2008 | 17 | 0.080 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2014 | 736 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2014 | 2019 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2004 | 5838 | 0.080 |
Why?
|
| Cell Proliferation | 5 | 2014 | 7303 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2014 | 6224 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 713 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2009 | 352 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1927 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2014 | 5804 | 0.070 |
Why?
|
| Piperazines | 3 | 2013 | 2131 | 0.070 |
Why?
|
| Transcription Factor RelA | 1 | 2007 | 185 | 0.070 |
Why?
|
| Cytarabine | 1 | 2013 | 1993 | 0.070 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2009 | 367 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 4245 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2009 | 480 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 3148 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2013 | 6245 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 1233 | 0.060 |
Why?
|
| Pyrimidines | 4 | 2013 | 3609 | 0.060 |
Why?
|
| Liver | 2 | 2013 | 2990 | 0.060 |
Why?
|
| Cytodiagnosis | 1 | 2006 | 224 | 0.060 |
Why?
|
| Proteomics | 2 | 2012 | 1423 | 0.060 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 7908 | 0.060 |
Why?
|
| Incidence | 1 | 2014 | 5904 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2008 | 1057 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2015 | 3596 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2003 | 184 | 0.050 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2003 | 27 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2014 | 16792 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 462 | 0.050 |
Why?
|
| Lymphocytosis | 1 | 2003 | 58 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2015 | 568 | 0.050 |
Why?
|
| Rhabdomyoma | 1 | 2002 | 22 | 0.050 |
Why?
|
| Adolescent | 4 | 2014 | 32336 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2003 | 140 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 5938 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2003 | 287 | 0.050 |
Why?
|
| Mutation | 2 | 2020 | 15642 | 0.050 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2002 | 64 | 0.050 |
Why?
|
| Imatinib Mesylate | 3 | 2013 | 1687 | 0.050 |
Why?
|
| Cell Survival | 3 | 2015 | 3062 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2007 | 781 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2004 | 834 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 14506 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2006 | 4862 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2013 | 590 | 0.050 |
Why?
|
| Vaginal Neoplasms | 1 | 2002 | 149 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 15198 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 681 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2003 | 567 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2004 | 690 | 0.050 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2020 | 37 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2006 | 1237 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8566 | 0.050 |
Why?
|
| Benzamides | 3 | 2013 | 1873 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2005 | 557 | 0.040 |
Why?
|
| Infant | 2 | 2014 | 13818 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2004 | 954 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5670 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 931 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 52 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 83 | 0.040 |
Why?
|
| Monocytes | 2 | 2013 | 786 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2020 | 247 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2005 | 835 | 0.040 |
Why?
|
| Neutrophils | 2 | 2013 | 845 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2018 | 9324 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2009 | 5295 | 0.040 |
Why?
|
| Transfection | 2 | 2015 | 2989 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 2260 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2003 | 1270 | 0.040 |
Why?
|
| Child | 3 | 2014 | 30200 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2005 | 4781 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 11817 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2003 | 2480 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 1225 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2379 | 0.030 |
Why?
|
| United States | 1 | 2014 | 16339 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 764 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2014 | 4343 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 5511 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2012 | 2114 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2020 | 39512 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1808 | 0.030 |
Why?
|
| Drug Stability | 1 | 2014 | 108 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 1106 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2012 | 16053 | 0.030 |
Why?
|
| bcl-Associated Death Protein | 1 | 2013 | 24 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2014 | 539 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 190 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 1701 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2006 | 7738 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 908 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2013 | 247 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2013 | 98 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 965 | 0.030 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2012 | 29 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2012 | 77 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2010 | 4887 | 0.020 |
Why?
|
| Polycomb-Group Proteins | 1 | 2011 | 42 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 489 | 0.020 |
Why?
|
| Integrases | 1 | 2013 | 267 | 0.020 |
Why?
|
| Transgenes | 1 | 2013 | 573 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 485 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 307 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 1006 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 4062 | 0.020 |
Why?
|
| Karyotyping | 1 | 2012 | 1022 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2011 | 160 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 2397 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 1422 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 394 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2010 | 224 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2011 | 259 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 2403 | 0.020 |
Why?
|
| Cyclohexanes | 1 | 2009 | 39 | 0.020 |
Why?
|
| Young Adult | 3 | 2013 | 22140 | 0.020 |
Why?
|
| Tyrosine | 1 | 2010 | 508 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2011 | 34238 | 0.020 |
Why?
|
| Fetus | 1 | 2013 | 616 | 0.020 |
Why?
|
| Histone Chaperones | 1 | 2009 | 32 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 7962 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 6196 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 1506 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1083 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 3107 | 0.020 |
Why?
|
| Tyrphostins | 1 | 2009 | 108 | 0.020 |
Why?
|
| Estrogens | 1 | 2012 | 758 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 13882 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 4071 | 0.020 |
Why?
|
| Time Factors | 1 | 2002 | 13266 | 0.020 |
Why?
|
| Neoplasms | 1 | 2013 | 15710 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 3666 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 5030 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 4932 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 4281 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 3483 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 4776 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 4895 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2005 | 256 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 6127 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2012 | 2056 | 0.020 |
Why?
|
| Giant Cells | 1 | 2005 | 68 | 0.020 |
Why?
|
| Mastectomy | 1 | 2011 | 1558 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 2499 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 1708 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 1462 | 0.010 |
Why?
|
| Interphase | 1 | 2003 | 145 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 3931 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 3960 | 0.010 |
Why?
|
| Epithelium | 1 | 2005 | 729 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 2003 | 79 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2003 | 228 | 0.010 |
Why?
|
| Perineum | 1 | 2002 | 110 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2003 | 304 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 587 | 0.010 |
Why?
|
| Pericardial Effusion | 1 | 2003 | 124 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 2084 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2010 | 1896 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2003 | 431 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2003 | 207 | 0.010 |
Why?
|
| Postmenopause | 1 | 2002 | 379 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 523 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2012 | 2955 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 9487 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 1848 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 5113 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 1642 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2002 | 1926 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 4925 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 5123 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 16270 | 0.010 |
Why?
|